Floatz logo

[Ac-225]-Psma-62

Hormone Sensitive Prostate Cancer

Eli Lilly and CompanyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Hormone Sensitive Prostate Cancer cohort.

Asset / SponsorPhaseRating
Mevrometostat
Pfizer
Phase 3B
shr7280
Jiangsu HengRui Medicine Co., Ltd.
Phase 1CC

Same molecule, other indications

[Ac-225]-Psma-62 is also rated in:

metastatic prostate carcinomaDormant
C
Indicative ·
37 / 100
View asset →
prostate cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →